synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
He launched tirades against international critics, particularly, United States President Barack Obama, the US government, the United Nations, and the European Union, which expressed condemnation to his unprecedented war on drugs that led to the deaths of about 3,300 people, half of which were killed by unknown assailants, and the arrest of 22,000 drug suspects and surrender of about 731,000 people.
There, he marveled at the geometric order and vast scale of the Pyramids of the Sun and the Moon, which he believed were constructed in accordance with astronomical observations. Humboldt measured the heights of these pyramids and studied their orientation, considering how the structures would have appeared a thousand years earlier, adorned with gilded images of gods. He was intrigued by the rubble of sun-baked bricks and pottery found within the pyramids, pondering their original purpose and construction techniques. Throughout his travels, Humboldt was deeply interested in the daily lives and cultural practices of Mexico’s indigenous peoples. He frequently inquired about local customs, tools, village names, and natural resources, filling his notebooks with details that even his native guide considered too elementary for a scholar. Receiving news from Berlin, Humboldt decided to postpone his plans for a global voyage due to damaged instruments, logistical difficulties, and the urgent pace of scientific progress in Europe. He resolved to remain in Mexico until spring 1804, making the most of his time by conducting local excursions and research. Humboldt’s scientific rigor was evident in his accurate astronomical and barometric measurements, which closely matched later calculations. In August 1803, he departed on an extensive tour, inspecting the Nochistongo canal, an engineering feat designed to protect Mexico City from floods, and collecting fossil remains for European scientists.
== Other products produced == The main products of malolactic fermentation are lactic acid, diacetyl, acetic acid, acetoin, and various esters. The amount and exact nature of these products depends on the species/strain of LAB conducting the malolactic fermentation and the condition influencing that wine (pH, available nutrients, oxygen levels, etc.). Some strains of O. oeni can synthesize higher alcohols which can contribute to fruity notes in the aroma of the wine. Additionally, some strains of the bacterium have beta-glucosidase enzymes that can break down monoglucosides which are aroma compounds attached to a sugar molecule. When the sugar component is cleaved, the rest of the compound becomes volatilized, meaning it can potentially be detected in the aroma bouquet of the wine. In the early 21st century, some strains of O. oeni were shown to use acetaldehyde by breaking it down into ethanol or acetic acid. While this may help for wines with excessive levels of acetaldehyde, for red wines, it can also destabilize the color of the wine by interfering with acetaldehyde's reaction with anthocyanins to create polymeric pigments that help create a wine's color.
== Measurement == 3-phosphoglycerate can be separated and measured using paper chromatography as well as with column chromatography and other chromatographic separation methods. It can be identified using both gas-chromatography and liquid-chromatography mass spectrometry and has been optimized for evaluation using tandem MS techniques.
In an RTG, heat generation cannot be varied with demand or shut off when not needed and it is not possible to save more energy for later by reducing the power consumption. Therefore, auxiliary power supplies (such as rechargeable batteries) may be needed to meet peak demand, and adequate cooling must be provided at all times including the pre-launch and early flight phases of a space mission. While spectacular failures like a nuclear meltdown or explosion are impossible with an RTG, there is still a risk of radioactive contamination if the rocket explodes or the device reenters the atmosphere and disintegrates. For terrestrial RTGs, damage by storms, seasonal ice, or vandalism are potential risks.
Sources: en.wikipedia.org
== External links == Engineered Pathogens and Unnatural Biological Weapons: The Future Threat of Synthetic Biology . Threats and considerations Synthetic biology books popular science book and textbooks Introductory Summary of Synthetic Biology Archived 2018-04-02 at the Wayback Machine. Concise overview of synthetic biology concepts, developments and applications Collaborative overview article on Synthetic Biology Controversial DNA startup wants to let customers create creatures (2015-01-03), San Francisco Chronicle It's Alive, But Is It Life: Synthetic Biology and the Future of Creation (28 September 2016), World Science Festival
Diski was a regular contributor to the London Review of Books; the collections Don't and Why Didn't You Do What You Were Told? collect articles and essays written for the publication. Her memoirs include In Gratitude, The Sixties, Skating to Antarctica, and Stranger on a Train: Daydreaming and Smoking around America With Interruptions, for which she won the 2003 Thomas Cook Travel Book Award. Benjamin Disraeli (1804–1881) novelist, poet, playwright, writer, and prime minister A prolific novelist, the 1840s Disraeli wrote a trilogy of novels with political themes. Coningsby attacks the evils of the Whig Reform Bill of 1832 and castigates the leaderless conservatives for not responding. Sybil; or, The Two Nations (1845) reveals Peel's betrayal over the Corn Laws. These themes are expanded in Tancred (1847). With Coningsby; or, The New Generation (1844). Isaac D'Israeli, (11 May 1766 – 19 January 1848) was a British writer, scholar and the father of British prime minister Benjamin Disraeli. He is best known for his essays and his associations with other men of letters. Michael Pinto-Duschinsky (born June 1943) Hungarian-born author, journalist, scholar, political consultant and writer. Anton Ehrenzweig (27 November 1908 – 5 December 1966) Austrian Jewish British author and theorist on modern art, psychoanalysis and Avant-garde music who wroteThe Psychoanalysis of Artistic Vision and Hearing (1953) and The Hidden Order of Art (1967).
Rodney Smith Markin (born 1956), is an American pathologist and authority in the field of laboratory automation. In 1993, he designed and created one of the world's first automated clinical laboratory specimen, device and analyzer management systems. In the mid-1990s, he chaired a standards group called the Clinical Testing Automation Standards Steering Committee (CTASSC) of the American Association for Clinical Chemistry, which later evolved into an area committee of the Clinical and Laboratory Standards Institute. Markin serves as the Vice President for Business Development and practices pathology at Nebraska Medicine, is associate vice chancellor for business development for the University of Nebraska Medical Center, and executive director of the UNeTech Institute of the University of Nebraska Medical Center and the University of Nebraska Omaha. He serves as both the David T. Purtilo Professor in the Department of Pathology and Microbiology in UNMC's College of Medicine as well as the Executive Director of the UNeTech Institute. Prior to his current position, he was the chief operating officier of the University of Nebraska system, the chief technology officer at UNMC, interim dean of the UNMC College of Medicine, board chairman and president and CEO of the Nebraska Medicine clinical practice plan (fka UNMC Physicians), an academic medical practice which includes more than 750 physicians, and has held several other administrative and academic positions at the University of Nebraska Medical Center.
Enzymes with this activity include flavanone 7-O-beta-glucosyltransferase, which uses UDP-glucose to transfer the sugar component. Flavanones like naringenin can undergo a rearrangement reaction which converts them first to the unstable hydroxlated isoflavanone, which loses water to give an isoflavone. The enzymes involved are isoflavonoid synthase and 2-hydroxyisoflavanone dehydratase.
Relative to 150 mg/day bicalutamide, levels of (R)-bicalutamide are about 15% higher at a dosage of 200 mg/day and about 50% higher at a dosage of 300 mg/day. In contrast to (R)-bicalutamide, the inactive enantiomer (S)-bicalutamide is much more rapidly absorbed (as well as cleared from circulation). Steady-state concentrations of the drug are reached after 4 to 12 weeks of administration independently of dosage, with an approximate 10- to 20-fold progressive accumulation of circulating levels of (R)-bicalutamide. The relatively long time to reach steady-state is a product of the long elimination half-life of bicalutamide. With single 50 mg and 150 mg doses of bicalutamide, mean peak concentrations (Cmax) of (R)-bicalutamide are 0.77 μg/mL (1.8 μmol/L) (at 31 hours) and 1.4 μg/mL (3.3 μmol/L) (at 39 hours), respectively. At steady-state, mean circulating concentrations (Css) of (R)-bicalutamide with 50 mg/day and 150 mg/day bicalutamide are 8.85 μg/mL (20.6 μmol/L) and 21.6 μg/mL (50.2 μmol/L), respectively. In another 150 mg/day bicalutamide study, mean circulating concentrations of (R)-bicalutamide were 19.4 μg/mL (45.1 μmol/L) and 28.5 μg/mL (66.3 μmol/L) on days 28 and 84 (weeks 4 and 12) of treatment, respectively. There is wide interindividual variability, up to 15.7-fold, in steady-state (R)-bicalutamide levels with bicalutamide therapy. This is the case for all dosage levels of bicalutamide, and ranges in (R)-bicalutamide levels for different dosages show significant overlap.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.